Prevalence of carnitine palmitoyltransferase 1A (CPT1A) variant p.P479L and risk of infant mortality in Nunavut, Northwest Territories, and Yukon

The p.P479L (c.1436C>T) variant of hepatic CPT1A is frequent in Inuit and British Columbia First Nations populations of Canada. CPT1A is a major regulatory point in long chain fatty acid oxidation in the liver. CPT1A deficiency is an autosomal recessive disorder that causes metabolic decompensati...

Full description

Bibliographic Details
Main Author: Collins, Sorcha Alexia
Format: Thesis
Language:English
Published: University of British Columbia 2011
Subjects:
Online Access:http://hdl.handle.net/2429/30525
id ftcanadathes:oai:collectionscanada.gc.ca:BVAU.2429/30525
record_format openpolar
spelling ftcanadathes:oai:collectionscanada.gc.ca:BVAU.2429/30525 2023-05-15T16:16:27+02:00 Prevalence of carnitine palmitoyltransferase 1A (CPT1A) variant p.P479L and risk of infant mortality in Nunavut, Northwest Territories, and Yukon Collins, Sorcha Alexia 2011-01-04T19:03:45Z http://hdl.handle.net/2429/30525 eng eng University of British Columbia http://hdl.handle.net/2429/30525 http://creativecommons.org/licenses/by-nc-nd/3.0/ Attribution-NonCommercial 2.5 Canada CC-BY-NC-ND Electronic Thesis or Dissertation 2011 ftcanadathes 2014-03-30T00:46:13Z The p.P479L (c.1436C>T) variant of hepatic CPT1A is frequent in Inuit and British Columbia First Nations populations of Canada. CPT1A is a major regulatory point in long chain fatty acid oxidation in the liver. CPT1A deficiency is an autosomal recessive disorder that causes metabolic decompensation triggered by fasting, which can progress to seizures and sudden death, if not treated. This study assesses prevalence and clinical impact of the P479L variant in the Canadian territories and reviews modifiable risk factors associated with infant mortality (IM) in Nunavut. Methods: Ethics approval was obtained from university REBs and local research institutes, with consultation with territorial Aboriginal groups. Newborn screening blood spots from all infants born in 2006 (n=1584) and sudden death in infancy cases (n=31; 1999-2008) in the territories were genotyped for the P479L variant. Results: P479L homozygosity in each territory was 64%, 3%, and 1% for Nunavut, NWT, and Yukon, respectively. Within NWT, homozygosity was highest in Inuvialuit (21%) and very low in First Nations (1%). Homozygosity in sudden death cases was highest in Nunavut (18/20) and associated with an increased risk (OR: 5.15; 95% CI: 1.19-22.38). Homozygosity was 29% for NWT cases (2/7), 67% in NWT Inuvialuit (2/3), and was not present in Yukon cases (0/4). Review of Nunavut IM cases (n=78; 1999-2008) identified Sudden Infant Death Syndrome (SIDS) and Sudden Unexpected Death in Infancy (SUDI) as the leading causes of infant death (47%), followed by death due to infectious disease (28%). At least 23% of IM cases were premature. Discussion: The P479L variant is very frequent in the Inuit/Inuvialuit of Canada. Although the sample size was small, there was an associated risk for sudden death in infants homozygous for the variant in Nunavut. SIDS and SUDI are the leading causes of infant death in Nunavut, followed by death due to infectious disease. Since deaths in these two categories are largely preventable, prevention strategies and further exploration into the P479L variant and other determinants are indicated. Management strategies, including newborn screening for the P479L variant, need to be developed in consultation with health authorities, local medical professionals, and local communities. Thesis First Nations inuit Inuvialuit Northwest Territories Nunavut Yukon Theses Canada/Thèses Canada (Library and Archives Canada) British Columbia ENVELOPE(-125.003,-125.003,54.000,54.000) Canada Northwest Territories Nunavut Yukon
institution Open Polar
collection Theses Canada/Thèses Canada (Library and Archives Canada)
op_collection_id ftcanadathes
language English
description The p.P479L (c.1436C>T) variant of hepatic CPT1A is frequent in Inuit and British Columbia First Nations populations of Canada. CPT1A is a major regulatory point in long chain fatty acid oxidation in the liver. CPT1A deficiency is an autosomal recessive disorder that causes metabolic decompensation triggered by fasting, which can progress to seizures and sudden death, if not treated. This study assesses prevalence and clinical impact of the P479L variant in the Canadian territories and reviews modifiable risk factors associated with infant mortality (IM) in Nunavut. Methods: Ethics approval was obtained from university REBs and local research institutes, with consultation with territorial Aboriginal groups. Newborn screening blood spots from all infants born in 2006 (n=1584) and sudden death in infancy cases (n=31; 1999-2008) in the territories were genotyped for the P479L variant. Results: P479L homozygosity in each territory was 64%, 3%, and 1% for Nunavut, NWT, and Yukon, respectively. Within NWT, homozygosity was highest in Inuvialuit (21%) and very low in First Nations (1%). Homozygosity in sudden death cases was highest in Nunavut (18/20) and associated with an increased risk (OR: 5.15; 95% CI: 1.19-22.38). Homozygosity was 29% for NWT cases (2/7), 67% in NWT Inuvialuit (2/3), and was not present in Yukon cases (0/4). Review of Nunavut IM cases (n=78; 1999-2008) identified Sudden Infant Death Syndrome (SIDS) and Sudden Unexpected Death in Infancy (SUDI) as the leading causes of infant death (47%), followed by death due to infectious disease (28%). At least 23% of IM cases were premature. Discussion: The P479L variant is very frequent in the Inuit/Inuvialuit of Canada. Although the sample size was small, there was an associated risk for sudden death in infants homozygous for the variant in Nunavut. SIDS and SUDI are the leading causes of infant death in Nunavut, followed by death due to infectious disease. Since deaths in these two categories are largely preventable, prevention strategies and further exploration into the P479L variant and other determinants are indicated. Management strategies, including newborn screening for the P479L variant, need to be developed in consultation with health authorities, local medical professionals, and local communities.
format Thesis
author Collins, Sorcha Alexia
spellingShingle Collins, Sorcha Alexia
Prevalence of carnitine palmitoyltransferase 1A (CPT1A) variant p.P479L and risk of infant mortality in Nunavut, Northwest Territories, and Yukon
author_facet Collins, Sorcha Alexia
author_sort Collins, Sorcha Alexia
title Prevalence of carnitine palmitoyltransferase 1A (CPT1A) variant p.P479L and risk of infant mortality in Nunavut, Northwest Territories, and Yukon
title_short Prevalence of carnitine palmitoyltransferase 1A (CPT1A) variant p.P479L and risk of infant mortality in Nunavut, Northwest Territories, and Yukon
title_full Prevalence of carnitine palmitoyltransferase 1A (CPT1A) variant p.P479L and risk of infant mortality in Nunavut, Northwest Territories, and Yukon
title_fullStr Prevalence of carnitine palmitoyltransferase 1A (CPT1A) variant p.P479L and risk of infant mortality in Nunavut, Northwest Territories, and Yukon
title_full_unstemmed Prevalence of carnitine palmitoyltransferase 1A (CPT1A) variant p.P479L and risk of infant mortality in Nunavut, Northwest Territories, and Yukon
title_sort prevalence of carnitine palmitoyltransferase 1a (cpt1a) variant p.p479l and risk of infant mortality in nunavut, northwest territories, and yukon
publisher University of British Columbia
publishDate 2011
url http://hdl.handle.net/2429/30525
long_lat ENVELOPE(-125.003,-125.003,54.000,54.000)
geographic British Columbia
Canada
Northwest Territories
Nunavut
Yukon
geographic_facet British Columbia
Canada
Northwest Territories
Nunavut
Yukon
genre First Nations
inuit
Inuvialuit
Northwest Territories
Nunavut
Yukon
genre_facet First Nations
inuit
Inuvialuit
Northwest Territories
Nunavut
Yukon
op_relation http://hdl.handle.net/2429/30525
op_rights http://creativecommons.org/licenses/by-nc-nd/3.0/
Attribution-NonCommercial 2.5 Canada
op_rightsnorm CC-BY-NC-ND
_version_ 1766002315451432960